Tirzepatide, a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist initially approved to treat type 2 diabetes, has demonstrated therapeutic potential as a safeguard against the adverse effects of doxorubicin
All tested compounds were found to cause eryptosis by externalizing PS and activating caspase-3
skin, hair, nails, lips, or mouth including gums, teeth, tongue, for the purpose of cleaning them, perfuming them, changing their appearance, correcting body odors or protecting them or keeping them in good condition. Singapore is one of the worlds most affluent markets in Asia and is considered a Showcase-Market for the introduction of Cosmetics to the rest of Southeast Asia
Am Fam Physician 102(6):355362 Dodd A, Hughes A, Sargant N, Whyte AF, Soar J, Turner PJ (2021) Evidence updates for the treatment of anaphylaxis